Ketamine Troches vs. Oral Tablets: What's the Difference?

Overview

Ketamine troches and oral ketamine tablets both deliver the same active medication — racemic ketamine hydrochloride — through the mouth, but they are designed to work in fundamentally different ways. The distinction centers on where absorption occurs: troches are held under the tongue for mucosal absorption, while tablets are swallowed and absorbed through the gastrointestinal tract.

This difference in absorption route has meaningful consequences for how much drug reaches the bloodstream, how quickly effects begin, and the overall therapeutic experience. Our article on troche absorption explains why sublingual delivery achieves higher bioavailability, and our sublingual technique guide covers how to maximize absorption.

How Each Format Works

Troches (Sublingual Delivery)

A troche is a compounded lozenge designed to dissolve slowly under the tongue or between the cheek and gum over 15-30 minutes. During dissolution, ketamine is absorbed through the highly vascularized sublingual and buccal mucosa directly into the bloodstream, bypassing the liver's first-pass metabolism.

The patient holds medicated saliva in the mouth to maximize mucosal contact. After dissolution, remaining saliva may be swallowed (adding some oral absorption) or spit out.

Oral Tablets (Swallowed)

An oral ketamine tablet or capsule is swallowed whole, like a standard medication. It travels through the esophagus to the stomach, where it dissolves, and is then absorbed through the intestinal wall into the portal vein. From there, it passes through the liver before reaching systemic circulation — the first-pass effect that significantly reduces bioavailability.

Bioavailability Comparison

The bioavailability difference means that a 200 mg troche held sublingually delivers approximately 50-60 mg of active ketamine to the bloodstream, while a swallowed 200 mg tablet delivers approximately 34-40 mg. This is a clinically relevant difference that affects both efficacy and dosing requirements.

Metabolite Profile

When ketamine passes through the liver (first-pass metabolism), it is extensively converted to norketamine and subsequently to hydroxynorketamine (HNK). While these metabolites may have their own therapeutic activity — particularly (2R,6R)-HNK, which has shown antidepressant properties in research — the ratio of parent drug to metabolites differs between routes:

• Troches: Higher ratio of unchanged ketamine to norketamine, because a greater portion enters systemic circulation without hepatic processing
• Oral tablets: Higher ratio of norketamine and HNK to unchanged ketamine, due to extensive first-pass metabolism

Whether one metabolite profile is therapeutically superior to the other remains an active research question. Some researchers hypothesize that the HNK contribution from oral dosing may provide sustained antidepressant effects, while the higher parent ketamine levels from sublingual dosing produce more robust acute effects.

Dosing Implications

Because of the bioavailability difference, achieving equivalent blood levels requires different doses:

• To achieve similar peak ketamine blood levels, an oral tablet dose would need to be approximately 30-50% higher than a sublingual troche dose
• Providers account for this when prescribing: a patient on 200 mg troches who switches to oral tablets might need 250-300 mg to maintain comparable effect

This is not simply a matter of taking more medication. Higher oral doses mean more drug passing through the liver, greater metabolite production, and potentially different side effect profiles (particularly more nausea, as the gastrointestinal tract processes a larger quantity of drug).

Practical Considerations

Technique Requirements

Troches require proper sublingual technique — placement, dissolution time, saliva management. Poor technique can significantly reduce bioavailability, effectively converting a sublingual dose into an oral one. Patients who struggle with technique (dry mouth conditions, difficulty holding saliva, oral pathology) may not achieve optimal sublingual absorption.

Oral tablets require no special technique — they are swallowed with water like any other medication. This simplicity is their primary advantage.

Session Experience

Troches produce a faster onset and more pronounced acute experience, including dissociative effects, due to the higher peak blood levels of unchanged ketamine. This is therapeutically desirable for many patients, particularly those using ketamine for depression where the acute neuroplastic effects are part of the therapeutic mechanism.

Oral tablets produce a slower, more gradual onset with potentially milder dissociative effects. Some patients and providers prefer this gentler profile, particularly for chronic pain applications where the goal is sustained analgesic activity rather than acute dissociative experience.

Nausea

Paradoxically, troches may cause less nausea than oral tablets for some patients, because less drug passes through the gastrointestinal system when absorption is primarily sublingual. However, swallowed saliva containing dissolved ketamine still reaches the stomach, so nausea remains possible with troches.

Oral tablets deliver the full dose to the stomach, which can increase nausea risk, particularly at higher doses.

When Each Format Is Appropriate

Troches are generally preferred when:

• Maximizing bioavailability within the oral route is important
• The acute dissociative experience is part of the therapeutic approach
• The patient can maintain proper sublingual technique
• Depression or anxiety is the primary indication

Oral tablets may be appropriate when:

• Sublingual technique is impractical (oral pathology, severe dry mouth, cognitive limitations)
• A slower onset and gentler experience is preferred
• The provider specifically wants higher metabolite-to-parent-drug ratios
• Chronic pain is the primary indication and sustained low-level effect is the goal

Key Takeaways

• Both formats deliver racemic ketamine, but through different absorption routes.
• Troches achieve 25-30% bioavailability via sublingual absorption; oral tablets achieve 17-20% via gastrointestinal absorption.
• The bioavailability difference is clinically significant and affects dosing, onset, and therapeutic experience.
• Troches require proper sublingual technique; oral tablets are simpler to administer.
• Most providers prefer troches for mental health indications due to superior bioavailability and faster onset.

References

• Sublingual and Oral Ketamine: A Systematic Review — Analysis of sublingual versus oral ketamine pharmacokinetics and clinical outcomes
• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology and routes of administration
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine pharmacokinetic data across routes
• MedlinePlus: Ketamine — National Library of Medicine drug information on ketamine formulations and proper use